New and Special Drug
-
Adempas (Riociguat) – CTEPH/PAH | HongKong DengYue Medicine
-
Biktarvy (Bictegravir/Emtricitabine/TAF) – HIV-1 | HongKong DengYue Medicine
-
Simulect (Basiliximab) – Renal Transplantation | HongKong DengYue Medicine
-
Enboke (Anti-Human Interleukin) – Inflammatory Skin Diseases | HongKong DengYue Medicine
-
Poteligeo (Mogamulizumab) – CTCL | HongKong DengYue Medicine
-
Rabineutra (Ormutivimab) – Rabies PEP | HongKong DengYue Medicine
-
Brii Biosciences (Amubarvimab) – COVID-19 | HongKong DengYue Medicine
-
SINTBILO (Tafolecimab) – Hypercholesterolemia | HongKong DengYue Medicine
-
Hansizhuang (Serplulimab) – Solid Tumors | HongKong DengYue Medicine
-
Ovidrel (rhCG) – Ovulation Induction | HongKong DengYue Medicine
-
CIMAher (Nimotuzumab) – HNSCC | HongKong DengYue Medicine
-
Dacogen (Decitabine) – Hematologic Malignancies | HongKong DengYue Medicine
-
Haiyitan (Glumetinib) – Lung Cancer (NSCLC) | HongKong DengYue Medicine
-
Junshida (Ongericimab) – Hypercholesterolemia | HongKong DengYue Medicine
-
Xolair (Omalizumab alfa) – Allergic diseases | HongKong DengYue Medicine
-
Remicade (Infliximab) – Autoimmune Diseases | HongKong DengYue Medicine
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights